Amedisys Given New $10.00 Price Target at RBC Capital (AMED)
Equities research analysts at RBC Capital increased their price target on shares of Amedisys (NASDAQ:AMED) from $7.00 to $10.00 in a research note issued to investors on Friday. The firm currently has an “underperform” rating on the stock. RBC Capital’s price target points to a potential downside of 35.82% from the company’s current price.
Amedisys (NASDAQ:AMED) opened at 15.58 on Friday. Amedisys has a 1-year low of $10.76 and a 1-year high of $18.70. The stock has a 50-day moving average of $14.75 and a 200-day moving average of $14.86. The company’s market cap is $511.2 million.
Amedisys (NASDAQ:AMED) last announced its earnings results on Thursday, May 8th. The company reported ($0.07) earnings per share for the quarter, missing the analysts’ consensus estimate of $0.56 by $0.63. The company had revenue of $298.74 million for the quarter, compared to the consensus estimate of $301.89 million. During the same quarter last year, the company posted $0.13 earnings per share. Amedisys’s revenue was down 9.1% compared to the same quarter last year. On average, analysts predict that Amedisys will post $0.06 earnings per share for the current fiscal year.
AMED has been the subject of a number of other recent research reports. Analysts at Deutsche Bank upgraded shares of Amedisys from a “sell” rating to a “hold” rating in a research note on Monday, June 30th. They now have a $14.00 price target on the stock, up previously from $8.00. Separately, analysts at CRT Capital upgraded shares of Amedisys from a “sell” rating to a “fair value” rating in a research note on Friday, June 27th. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Amedisys in a research note on Wednesday, June 25th. They now have a $14.00 price target on the stock. One investment analyst has rated the stock with a sell rating and six have given a hold rating to the stock. Amedisys has an average rating of “Hold” and a consensus price target of $12.50.
Amedisys, Inc (NASDAQ:AMED) is a health care company focused on bringing home the continuum of care.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.